Diaa Abdel Hakim, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ultrasonography, Interventional | 11 | 2024 | 1486 | 1.750 |
Why?
|
Plaque, Atherosclerotic | 6 | 2024 | 1519 | 1.090 |
Why?
|
Coronary Artery Disease | 12 | 2024 | 6487 | 0.970 |
Why?
|
Drug-Eluting Stents | 3 | 2017 | 753 | 0.720 |
Why?
|
Coronary Vessels | 10 | 2024 | 3107 | 0.640 |
Why?
|
Coronary Angiography | 10 | 2024 | 4577 | 0.480 |
Why?
|
Stents | 6 | 2022 | 3280 | 0.480 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2022 | 1873 | 0.410 |
Why?
|
Echocardiography, Transesophageal | 1 | 2017 | 1133 | 0.390 |
Why?
|
Intraoperative Complications | 1 | 2017 | 1198 | 0.370 |
Why?
|
Coronary Restenosis | 1 | 2012 | 424 | 0.360 |
Why?
|
Fractional Flow Reserve, Myocardial | 2 | 2020 | 290 | 0.260 |
Why?
|
Aortic Valve Stenosis | 1 | 2017 | 1965 | 0.260 |
Why?
|
Thrombocytopenia | 1 | 2011 | 1179 | 0.220 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 15076 | 0.160 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 3508 | 0.130 |
Why?
|
Area Under Curve | 1 | 2017 | 1654 | 0.110 |
Why?
|
Aortic Valve Insufficiency | 1 | 2017 | 579 | 0.110 |
Why?
|
Myocardial Infarction | 2 | 2012 | 11727 | 0.110 |
Why?
|
Tubulin Modulators | 1 | 2012 | 110 | 0.100 |
Why?
|
Coronary Occlusion | 1 | 2014 | 304 | 0.100 |
Why?
|
Treatment Outcome | 8 | 2022 | 63114 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2023 | 4456 | 0.090 |
Why?
|
ROC Curve | 1 | 2017 | 3527 | 0.090 |
Why?
|
Heart | 1 | 2023 | 4467 | 0.090 |
Why?
|
Hyperplasia | 1 | 2012 | 1185 | 0.090 |
Why?
|
Graft Occlusion, Vascular | 1 | 2012 | 549 | 0.080 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2012 | 361 | 0.080 |
Why?
|
Prospective Studies | 4 | 2024 | 53288 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2017 | 6365 | 0.080 |
Why?
|
Prosthesis Failure | 1 | 2012 | 1206 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2020 | 2337 | 0.070 |
Why?
|
Humans | 18 | 2024 | 744343 | 0.070 |
Why?
|
Ultrasonography | 1 | 2020 | 5985 | 0.070 |
Why?
|
Tomography, Optical Coherence | 2 | 2020 | 2657 | 0.070 |
Why?
|
Ticlopidine | 1 | 2012 | 899 | 0.070 |
Why?
|
Monitoring, Intraoperative | 1 | 2012 | 957 | 0.070 |
Why?
|
Paclitaxel | 1 | 2012 | 1708 | 0.060 |
Why?
|
Female | 10 | 2023 | 380194 | 0.060 |
Why?
|
Severity of Illness Index | 2 | 2017 | 15540 | 0.050 |
Why?
|
Blood Platelets | 1 | 2012 | 2508 | 0.050 |
Why?
|
Image Enhancement | 1 | 2012 | 2921 | 0.050 |
Why?
|
Male | 10 | 2017 | 350118 | 0.050 |
Why?
|
Aged | 6 | 2017 | 163280 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 1 | 2023 | 20129 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2012 | 3068 | 0.040 |
Why?
|
Electrocardiography | 1 | 2012 | 6442 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2012 | 3110 | 0.040 |
Why?
|
Risk Factors | 5 | 2024 | 72290 | 0.040 |
Why?
|
Risk Assessment | 2 | 2017 | 23338 | 0.040 |
Why?
|
Prognosis | 1 | 2017 | 29063 | 0.040 |
Why?
|
Middle Aged | 7 | 2017 | 213383 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2012 | 39050 | 0.040 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2020 | 721 | 0.030 |
Why?
|
Cohort Studies | 1 | 2017 | 40561 | 0.030 |
Why?
|
Hemodynamics | 1 | 2023 | 4199 | 0.030 |
Why?
|
Time Factors | 2 | 2012 | 40075 | 0.030 |
Why?
|
Linear Models | 2 | 2013 | 5952 | 0.030 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2012 | 132 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2012 | 379 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2012 | 229 | 0.020 |
Why?
|
Republic of Korea | 1 | 2013 | 539 | 0.020 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 297 | 0.020 |
Why?
|
Platelet Function Tests | 1 | 2012 | 270 | 0.020 |
Why?
|
New York City | 1 | 2012 | 710 | 0.020 |
Why?
|
Peroxidase | 1 | 2012 | 611 | 0.020 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2012 | 638 | 0.020 |
Why?
|
Platelet Aggregation | 1 | 2012 | 798 | 0.020 |
Why?
|
Japan | 1 | 2013 | 1360 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2013 | 789 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2012 | 77449 | 0.020 |
Why?
|
Drug Resistance | 1 | 2012 | 1609 | 0.020 |
Why?
|
Equipment Design | 1 | 2014 | 3582 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2012 | 4776 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2012 | 3200 | 0.010 |
Why?
|
Reoperation | 1 | 2012 | 4201 | 0.010 |
Why?
|
Lipids | 1 | 2013 | 3305 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12245 | 0.010 |
Why?
|
Cytokines | 1 | 2012 | 7322 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12959 | 0.010 |
Why?
|
Registries | 1 | 2012 | 8089 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 19905 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2012 | 15295 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 11725 | 0.010 |
Why?
|
Heart Failure | 1 | 2012 | 10900 | 0.000 |
Why?
|
United States | 1 | 2013 | 69872 | 0.000 |
Why?
|